Avastin (bevacizumab) - Angiogenesis Inhibitor and Cancer Therapy
Key Data:
Drug (Brand / Generic)
Avastin (bevacizumab)
Company / Licensee
Genentech / Roche
Therapy Class
Angiogenesis inhibitor
Product Description
Humanised anti-VEGF MAb
Current Indications
Colorectal, breast, lung and renal cell carcinoma
Market Sector
Oncology
Development Status
Approved in the US, Europe and other major markets
